| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/26/2002 | CA2441503A1 Method for cleaving human growth hormone gh |
| 09/26/2002 | CA2441428A1 Highly purified and crystalline form of harringtonine |
| 09/26/2002 | CA2441427A1 Biurethane derivatives |
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2441042A1 Monoclonal antibody therapy for pancreas cancer |
| 09/26/2002 | CA2440954A1 Phenyl derivatives 3 |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440391A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2440106A1 Substituted benzopyranones as telomerase inhibitors |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439539A1 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage) |
| 09/26/2002 | CA2438308A1 Peg-conjugates of hgf-nk4 |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435664A1 Ncc2705-the genome of a bifidobacterium |
| 09/26/2002 | CA2430619A1 Farnesyltransferase inhibitors |
| 09/26/2002 | CA2403903A1 Angiogenesis inhibitors |
| 09/25/2002 | EP1243655A1 Modified HPV E6 and E7 genes and proteins useful for vaccination |
| 09/25/2002 | EP1243650A2 Process for constructing a cdna library, and a polypeptide and dna coding for the same |
| 09/25/2002 | EP1243586A1 Phloridzin-rich phenolic fraction and its use as cosmetic, food or nutritional agent |
| 09/25/2002 | EP1243583A1 Heterocyclic compounds having sulfonamide groups |
| 09/25/2002 | EP1243290A2 Modulation of gene expression by combination therapy |
| 09/25/2002 | EP1243289A2 Modulation of gene expression by combination therapy |
| 09/25/2002 | EP1243276A1 Elongated and multiple spacers containing activatible prodrugs |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1242823A2 Selecting library members capable of binding to epitopes |
| 09/25/2002 | EP1242617A2 Method of classifying a thyroid carcinoma using differential gene expression |
| 09/25/2002 | EP1242600A1 Cytokine zcyto18 |
| 09/25/2002 | EP1242596A1 Methods and materials relating to novel von willebrand/thrombospondin-like polypeptides and polynucleotides |
| 09/25/2002 | EP1242592A2 A molecular switch for regulating mammalian gene expression |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242584A2 Human kinases |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242458A2 Brain specific binding members |
| 09/25/2002 | EP1242456A2 Scfv antibodies against disease associated molecules |
| 09/25/2002 | EP1242455A1 N-alkylated peptides having antiangiogenic activity |
| 09/25/2002 | EP1242451A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 09/25/2002 | EP1242449A1 Modified adenovirus fibre and uses |
| 09/25/2002 | EP1242445A1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds and pharmaceutical preparation containing said compounds |
| 09/25/2002 | EP1242438A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242409A2 Substituted bisindolylmaleimides |
| 09/25/2002 | EP1242408A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242401A1 Cytotoxic agents comprising taxanes and their therapeutic use |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242389A2 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242379A1 Curcumin analogues for treating cancer |
| 09/25/2002 | EP1242374A1 Acryloyl peptidic derivatives, process for their preparation and their use as antitumor agents |
| 09/25/2002 | EP1242372A1 Inhibitors of farnesyl protein transferase |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242366A1 Salicylamides as serine protease and factor xa inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242352A2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| 09/25/2002 | EP1242116A2 Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| 09/25/2002 | EP1242110A1 A method and composition for treating prostate cancer |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242102A2 Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
| 09/25/2002 | EP1242060A1 Treatment of metastatic disease |
| 09/25/2002 | EP1242049A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 09/25/2002 | EP1241935A2 Methods for producing transgenic animals |
| 09/25/2002 | EP1146897B1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair |
| 09/25/2002 | EP1070059B1 Chromanone and thiochromanone derivatives |
| 09/25/2002 | EP1001951B1 Thiazole derivatives, method for their production and use |
| 09/25/2002 | EP0986390B1 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 09/25/2002 | EP0977559B1 Enhanced anti-cancer agent delivery to solid tumors by primer compounds |
| 09/25/2002 | EP0948345B1 Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction |
| 09/25/2002 | EP0923570B1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives |
| 09/25/2002 | EP0915870B1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 09/25/2002 | EP0904087B1 Phosphatidic acid-comprising compositions |
| 09/25/2002 | EP0871656B1 Dolastatin derivatives, their preparation and use |
| 09/25/2002 | EP0841912B1 Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(substituted)hydrazines |
| 09/25/2002 | EP0835258B1 Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues |
| 09/25/2002 | EP0835257B1 Intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds |
| 09/25/2002 | EP0746312B1 Guanylhydrazones for treating inflammatory conditions |
| 09/25/2002 | CN1371421A Tankyrase 2 materials and methods |
| 09/25/2002 | CN1371416A Human CTLA-4 antibodies and their uses |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371388A Hexapeptide with stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation differentiation and apoptosis |
| 09/25/2002 | CN1371379A New indolocarbazole alkaloids from marine actinomycete |
| 09/25/2002 | CN1371372A Novel chalcones |
| 09/25/2002 | CN1371371A Novel derivatives of flavones, xanthones and coumarins |
| 09/25/2002 | CN1371370A Chalcone coumarins |
| 09/25/2002 | CN1371366A Benzamide formulation with histone deacetylase inhibitor activity |